DR Congo rolls out Ebola vaccine for health workers as death toll rises

Background on the current Ebola outbreak

Since early 2024 the Democratic Republic of the Congo (DRC) has reported a surge in Ebola virus disease cases caused by a variant that differs from the strain targeted by the vaccine used in previous outbreaks. Health authorities say the new strain spreads more quickly and has a higher fatality rate, prompting urgent action.

The World Health Organization (WHO) estimates that the outbreak has already claimed more than 150 lives, with dozens of new cases reported each week. Communities in the provinces of North Kivu and Ituri remain the most affected, where limited health infrastructure hampers rapid response.

Why vaccinating health workers matters

Health workers are at the front line of any epidemic. Their exposure risk is high because they provide care in crowded clinics, conduct contact tracing, and transport patients across long distances. Protecting them reduces transmission chains and maintains essential services.

In the DRC, more than 70 percent of recent Ebola cases have been linked to health‑care settings. By vaccinating staff, the Ministry of Health hopes to break that pattern and restore public confidence in the health system.

Target groups for the new vaccine

Doctors, nurses and midwives working in hospitals and health centres
Laboratory technicians handling patient samples
Community health volunteers who conduct house‑to‑house visits
Logistics personnel responsible for moving supplies and specimens

Details of the vaccination campaign

The campaign aims to administer the vaccine to 50,000 frontline staff across the most affected provinces. The vaccine, developed by a consortium of research institutes, is designed to protect against the new Ebola variant.

Vaccination sites have been set up in provincial capitals and major towns. Mobile teams travel to remote villages, ensuring that even staff in hard‑to‑reach areas receive the jab.

Logistics and cold‑chain management

Maintaining the vaccine at the required temperature is a major challenge in a country where electricity supply is often unreliable. To address this, the program uses solar‑powered refrigerators and portable cool boxes that can keep the vaccine stable for up to two weeks without external power.

Local partners, including the International Committee of the Red Cross, are training health workers on proper handling and documentation procedures.

Clinical trial component

Alongside the mass rollout, a one year clinical trial is enrolling 20,000 volunteers. The trial will assess the vaccine’s safety, immune response durability, and effectiveness against the new strain.

Participants receive the vaccine under strict monitoring. Follow‑up visits are scheduled at one month, six months and twelve months after injection. Data from the trial will be shared with global health agencies to inform future vaccination strategies.

Key objectives of the trial

Measure the level of antibodies produced after vaccination
Track any adverse events among participants
Compare infection rates between vaccinated and unvaccinated health workers
Provide evidence for possible expansion of the vaccine to the general population

International support and partnerships

The effort is supported by a coalition of international partners. The WHO provides technical guidance and helps coordinate cross‑border surveillance. The United Nations Children’s Fund (UNICEF) assists with cold‑chain equipment and community outreach.

Funding comes from the Global Fund, the European Union and several private donors. In addition, research institutions in the United States and Europe contribute expertise on vaccine development and trial design.

Authoritative sources

For more information on Ebola virus disease and vaccination strategies, see the World Health Organization fact sheet and the Centers for Disease Control and Prevention Ebola overview. The DRC Ministry of Health regularly updates case numbers on its official website. A recent analysis of vaccine efficacy was published in The Lancet.

Challenges ahead

While the vaccine rollout marks a significant step forward, several obstacles remain. Vaccine hesitancy persists in some communities due to misinformation and fear. Security concerns, especially in conflict‑affected areas, can limit access for health teams.

Furthermore, the virus’s ability to mutate raises the possibility that future variants could evade current vaccine protection. Continuous genomic surveillance is therefore essential.

Strategies to address obstacles

Engage local leaders and religious figures to promote vaccine acceptance
Deploy security escorts for mobile vaccination teams in high‑risk zones
Strengthen laboratory capacity for rapid sequencing of viral samples
Maintain transparent communication about side effects and trial results

What the rollout means for the region

Protecting health workers is expected to reduce the overall transmission rate, allowing other public health programs—such as routine immunizations and maternal care—to resume without interruption.

Economically, a healthier workforce supports agricultural production and trade, which are vital for food security in the DRC. International investors also view a stable health environment as a positive sign for future development projects.

Ultimately, the success of this campaign could serve as a model for other countries confronting emerging Ebola threats.